Clinuvel Pharmaceuticals Ltd (CUV) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Clinuvel Pharmaceuticals Ltd A$24.38, price A$8.26, upside +195.2%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Clinuvel Pharmaceuticals Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range A$8.01 – A$43.02 · fair‑value band A$16.24 – A$43.32 · the A$8.26 price screens below the A$24.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Clinuvel Pharmaceuticals in your weekly email
Every Wednesday you see whether Clinuvel Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
Show more
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Stock analysis
Clinuvel Pharmaceuticals Ltd (CUV) currently trades at A$8.26, while our model-based Fair Value estimate is A$24.38, implying the stock looks roughly 66.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of A$33.33 per share, and 21 of the 26 models we run sit above the A$8.26 price.
Bear case: the Asset-Based group reads lowest at A$3.20, and 5 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: A$16.24 (bear) to A$43.32 (bull), the price of A$8.26 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Clinuvel Pharmaceuticals Ltd reported revenue of A$95.0M in FY2025 versus A$48.0M in FY2021, a compound +18.6%/yr. Reported net income was A$36.2M in FY2025, compounding +10.0%/yr from FY2021.
Key figures
Market cap A$500M (≈ $351M) · P/E ratio 12.9 · P/S ratio 4.91 · EPS (TTM) A$0.6400 · Dividend yield 0.6% · Net margin 38.1% · Return on equity 14.0% · Return on assets (EBIT) 21.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 195%, CUV screens cheaper than that median.
Fair Value models
Bear A$16.24Fair Value A$24.38Bull A$43.32
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (A$0.5900 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.92/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.9%
Start year 2020 (pandemic). Over 10 years: +39.9% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+15.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.5%
Dividend (yield on the price)0.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.31% → 48%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−16.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about −18.6% a year for the price and +1.8% for the forecasts.
Compare Clinuvel Pharmaceuticals Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside+195% · Top 25%
Profitability
Return on equity (TTM)14% · Top 25%
Return on assets11% · Top 25%
Net margin (TTM)34% · Top 25%
Operating margin (TTM)37% · Top 25%
Growth and dividend
Revenue growth4% · Above median
Dividend yield (TTM)0.6% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Clinuvel Pharmaceuticals Ltd (CUV) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of A$24.38 versus a price of A$8.26, about +195% upside (undervalued).
What is the fair value of CUV?
Our model-based fair value for Clinuvel Pharmaceuticals Ltd is A$24.38 (as of Sep 23, 2026), built from audited fundamentals. The current price: A$8.26.
What is the quality score of CUV?
Clinuvel Pharmaceuticals Ltd has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Clinuvel Pharmaceuticals Ltd (CUV)?
Our model-based price target is the fair value of A$24.38 (as of Sep 23, 2026) from 26 valuation models. Cautious scenario A$16.24, optimistic scenario A$43.32. It is a calculation from audited fundamentals, not an analyst target.
What is the Clinuvel Pharmaceuticals Ltd stock forecast for 2026?
Our models put fair value at A$24.38, about +195% upside versus a price of A$8.26 (undervalued). Cautious scenario A$16.24, optimistic scenario A$43.32. The calculation is refreshed regularly with new filings.
What is the revenue of Clinuvel Pharmaceuticals Ltd (CUV)?
Clinuvel Pharmaceuticals Ltd reported trailing-twelve-month revenue of about A$96.3M (latest available figure, as of Sep 23, 2026).
Does Clinuvel Pharmaceuticals Ltd pay a dividend?
Clinuvel Pharmaceuticals Ltd currently shows a dividend yield of about 0.61% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Clinuvel Pharmaceuticals Ltd (CUV)?
For today's price to be fair in a discounted-cash-flow model, Clinuvel Pharmaceuticals Ltd would have to grow free cash flow by -16.2 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +23.9 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of CUV use?
Our models discount Clinuvel Pharmaceuticals Ltd at 9.9 %: a base by market capitalisation (small), damped by beta 0.61, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Clinuvel Pharmaceuticals Ltd that is -16.2 % per year a year over ten years, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has Clinuvel Pharmaceuticals Ltd (CUV) delivered so far?
Over the past 5 years revenue at Clinuvel Pharmaceuticals Ltd grew +23.9 % a year. The price currently implies -16.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Clinuvel Pharmaceuticals Ltd (CUV) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Clinuvel Pharmaceuticals Ltd (-16.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Clinuvel Pharmaceuticals Ltd (CUV)?
The free-cash-flow yield on the price is 9.80 %: that much free cash flow Clinuvel Pharmaceuticals Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Clinuvel Pharmaceuticals Ltd (CUV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Clinuvel Pharmaceuticals Ltd it is A$24.38 per share (as of Sep 23, 2026), against a price of A$8.26. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Clinuvel Pharmaceuticals Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CUV trades below its calculated fair value: price A$8.26, fair value A$24.38, a gap of about +195% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CUV?
No. The price is what the market pays today (A$8.26); the fair value is what the company's own numbers justify (A$24.38). For Clinuvel Pharmaceuticals Ltd the two are A$16.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is Clinuvel Pharmaceuticals Ltd worth?
The market values Clinuvel Pharmaceuticals Ltd at about A$500M (market capitalisation, as of Sep 23, 2026). Per share that is A$8.26; our models calculate a fair value of A$24.38 per share.
What do the bullish and bearish scenarios say about CUV?
Our models span a range for Clinuvel Pharmaceuticals Ltd: cautious scenario A$16.24, base A$24.38, optimistic A$43.32 per share (as of Sep 23, 2026, price A$8.26). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CUV?
Clinuvel Pharmaceuticals Ltd trades at a price-to-earnings ratio of 12.9 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of A$24.38 is built from several models across several years. Other multiples: PEG 0.6, P/B 1.5, P/S 3.6, EV/EBITDA 2.9.
What is the PEG ratio of CUV?
The PEG ratio of Clinuvel Pharmaceuticals Ltd is 0.65 (P/E divided by earnings growth, as of Sep 23, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Clinuvel Pharmaceuticals Ltd (CUV)?
Balance-sheet figures for Clinuvel Pharmaceuticals Ltd (as of Sep 23, 2026): return on equity 14.0%. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is CUV from its 52-week high?
Clinuvel Pharmaceuticals Ltd trades at A$8.26, about 38% below its 52-week high of A$13.23 and 3% above the low of A$8.01 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$24.38 is for.
Which stocks are comparable to Clinuvel Pharmaceuticals Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Clinuvel Pharmaceuticals Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price A$8.26, calculated fair value A$24.38 (+195%), Quality Score 66/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CUV calculated?
We run Clinuvel Pharmaceuticals Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$24.38, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Clinuvel Pharmaceuticals Ltd currently trades 195 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Clinuvel Pharmaceuticals Ltd (CUV)?
The closing price on Sep 24, 2026 was A$8.26. Our model-based fair value is A$24.38, about +195% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Clinuvel Pharmaceuticals Ltd right now?
The price is below even our cautious bear case (A$16.24). The market is more pessimistic than our downside scenario. The model range is unusually wide (A$16.24 to A$43.32). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Clinuvel Pharmaceuticals Ltd
How large is the market capitalisation of Clinuvel Pharmaceuticals Ltd (CUV)?
The market capitalisation of Clinuvel Pharmaceuticals Ltd is A$500M (≈ $351M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Clinuvel Pharmaceuticals Ltd (CUV)?
The price-to-sales ratio of Clinuvel Pharmaceuticals Ltd is 4.91 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Clinuvel Pharmaceuticals Ltd (CUV)?
Earnings per share at Clinuvel Pharmaceuticals Ltd are A$0.6400 (price ÷ EPS = P/E 12.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Clinuvel Pharmaceuticals Ltd (CUV)?
The dividend yield of Clinuvel Pharmaceuticals Ltd is 0.6% (payout 7.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Clinuvel Pharmaceuticals Ltd (CUV)?
The net margin of Clinuvel Pharmaceuticals Ltd is 38.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Clinuvel Pharmaceuticals Ltd (CUV)?
The return on equity (ROE) of Clinuvel Pharmaceuticals Ltd is 14.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Clinuvel Pharmaceuticals Ltd (CUV)?
On an EBIT basis the return on assets of Clinuvel Pharmaceuticals Ltd is 21.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Clinuvel Pharmaceuticals Ltd (CUV)?
The operating margin of Clinuvel Pharmaceuticals Ltd is 36.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Clinuvel Pharmaceuticals Ltd (CUV)?
Revenue at Clinuvel Pharmaceuticals Ltd is growing +3.6% versus a year earlier (3y avg +13.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Clinuvel Pharmaceuticals Ltd (CUV)?
Earnings per share at Clinuvel Pharmaceuticals Ltd are growing −26.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Clinuvel Pharmaceuticals Ltd (CUV) hold?
Clinuvel Pharmaceuticals Ltd holds more cash than debt, A$224M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Clinuvel Pharmaceuticals Ltd in the live analysis
One click puts Clinuvel Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 23, 2026